What is Zacks Research’s Estimate for Exelixis Q4 Earnings?

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at Zacks Research reduced their Q4 2026 earnings per share (EPS) estimates for Exelixis in a report issued on Wednesday, August 26th. Zacks Research analyst Team now expects that the biotechnology company will earn $0.81 per share for the quarter, down from their previous forecast of $0.83. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $3.18 per share. Zacks Research also issued estimates for Exelixis’ Q2 2027 earnings at $0.84 EPS and Q3 2027 earnings at $0.93 EPS.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.85 by $0.06. The business had revenue of $628.69 million for the quarter, compared to the consensus estimate of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The company’s revenue was up 10.6% on a year-over-year basis. During the same period last year, the business posted $0.75 EPS.

Several other analysts also recently weighed in on EXEL. Leerink Partners downgraded Exelixis from an “outperform” rating to a “market perform” rating and set a $52.00 target price for the company. in a research note on Thursday, August 6th. BMO Capital Markets started coverage on Exelixis in a research note on Tuesday, August 18th. They set a “market perform” rating and a $54.00 price objective for the company. Wells Fargo & Company lifted their price objective on Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a report on Monday, July 13th. HC Wainwright reaffirmed a “buy” rating and issued a $56.00 target price on shares of Exelixis in a research report on Thursday, July 2nd. Finally, Wall Street Zen cut Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Exelixis currently has a consensus rating of “Hold” and a consensus target price of $50.07.

Exelixis Stock Down 1.1%

EXEL opened at $56.10 on Thursday. The firm’s 50 day moving average is $54.46 and its 200-day moving average is $48.88. Exelixis has a 52-week low of $33.76 and a 52-week high of $57.57. The firm has a market capitalization of $13.90 billion, a P/E ratio of 17.64, a P/E/G ratio of 1.69 and a beta of 0.44.

Insider Transactions at Exelixis

In related news, Director Sue Gail Eckhardt sold 9,812 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $50.14, for a total value of $491,973.68. Following the completion of the sale, the director directly owned 16,079 shares of the company’s stock, valued at $806,201.06. The trade was a 37.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mary C. Beckerle sold 9,812 shares of Exelixis stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the transaction, the director owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. The trade was a 37.90% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 23,549 shares of company stock valued at $1,216,894. Insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Exelixis

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Exelixis in the second quarter worth about $1,581,991,000. California State Teachers Retirement System boosted its stake in Exelixis by 4,875.6% in the second quarter. California State Teachers Retirement System now owns 14,785,373 shares of the biotechnology company’s stock valued at $804,472,000 after acquiring an additional 14,488,217 shares during the period. AQR Capital Management LLC grew its holdings in shares of Exelixis by 48.8% during the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock valued at $598,647,000 after purchasing an additional 4,477,029 shares during the last quarter. Norges Bank bought a new position in shares of Exelixis during the fourth quarter valued at approximately $106,460,000. Finally, Caisse de depot et placement du Quebec acquired a new stake in shares of Exelixis during the 2nd quarter worth approximately $113,951,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.